Add like
Add dislike
Add to saved papers

Establishing an updated core domain set for studies in juvenile idiopathic arthritis: a report from the OMERACT 2018 JIA Workshop.

Journal of Rheumatology 2019 Februrary 16
OBJECTIVE: The current Juvenile Idiopathic Arthritis (JIA) Core Set used in randomized controlled trials (RCTs) and longitudinal observational studies (LOS) was developed without input of patients/parents. At OMERACT 2016, a special interest group voted to reconsider the core set incorporating broader stakeholder input. We describe subsequent work culminating in an OMERACT 2018 plenary and consensus voting.

METHODS: Candidate domains were identified through literature review, qualitative surveys, and online discussion boards (ODBs) held with JIA patients and parents in Australia, Italy, and the USA. A Delphi process with parents, patients, health care providers, researchers and regulators served to edit the domain list and prioritize candidate domains. After presentation of results, OMERACT workshop participants voted with consensus set at > 70%.

RESULTS: Participants in ODBs were 53 JIA patients (ages 15-24 years) and 55 parents. Three rounds of Delphi considering 27 domains were completed by 190 (response rate 85%), 201 (84%) and 182 (77%) stakeholders, respectively, from 50 countries. There was discordance noted between domains prioritized by patient/parents compared to other stakeholders. OMERACT conference voting approved domains for JIA RCTs and LOS with 83% endorsement. Mandatory domains are: pain, joint inflammatory signs, activity limitation/physical function, patient perception of disease activity (overall well-being), and adverse events. Mandatory in specific circumstances: Inflammation/other features relevant to specific JIA categories.

CONCLUSION: Following OMERACT methodology we developed an updated JIA Core Domain Set. Next steps are to identify and systematically evaluate best outcome measures for these domains.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app